Mereo BioPharma gives Q3 2026 update on setrusumab and alvelestat regulatory talksNov 9Quarterly updateMereo BioPharma Group plc
Mereo BioPharma and Sentynl sign option deal for alvelestat in lung diseaseAug 11PartnershipMereo BioPharma Group plc
Mereo BioPharma reports Q2 2026 results, alvelestat licensing deal with SentynlAug 11Quarterly updateMereo BioPharma Group plc